Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-meso in mesothelin expressing cancers
NCT02159716Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Jun 2014
- Primary completion
- Nov 2015
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART-meso cells in pancreatic ductal adenocarcinoma (PDAC), Serous Epithelial Ovarian Cancer (SOC) and malignant pleural mesothelioma (MPM) (3 arms), sponsored by University of Pennsylvania. Primary endpoint: Number of Adverse Events at 2 years. Started Jun 2014; status: completed.
02
Drugs
CART-meso cells
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)Serous Epithelial Ovarian Cancer (SOC)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02159716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02159716.